MBBS OSCE · General Medicine / Neurology

Multiple sclerosis — newly-diagnosed counselling OSCE station (NEET-PG/INICET)

An MBBS OSCE station testing counselling of a woman newly diagnosed with relapsing-remitting MS: explaining the diagnosis and prognosis, the role and risks of disease-modifying therapy (including NMOSD exclusion and natalizumab/PML), pregnancy and family planning, driving, lifestyle (vitamin D, smoking), and the multidisciplinary follow-up plan.

10 min stationVerification in progress
On this page
Study tools

Exam tags

NEET-PGINICET

Candidate instructions

You are the doctor in the neurology clinic. A 28-year-old woman has just been diagnosed with relapsing-remitting multiple sclerosis after an optic-neuritis episode and a typical brain MRI. She takes the combined oral contraceptive pill, drives to work, and hopes to start a family in two to three years. You have 8 minutes to assess and counsel her, and 2 minutes for examiner questions.

Candidate tasks

  1. Explain the diagnosis (RRMS) and the prognosis in honest but reassuring terms.
  2. Outline the role and risks of disease-modifying therapy (DMT), including the need to exclude NMOSD/MOGAD before starting and the natalizumab PML risk.
  3. Address pregnancy and family planning, driving, and lifestyle measures (vitamin D, smoking cessation).
  4. Describe symptomatic support and a multidisciplinary follow-up plan.
  5. Communicate clearly and empathetically, check understanding, and provide a safety-net (what to do in a relapse).

Examiner checklist (mark each as done / partial / not done)

  • Explains that RRMS is a relapsing-remitting, immune-mediated demyelinating disease, that relapses typically recover, and that modern DMTs have markedly improved outcomes — honest yet reassuring.[2]
  • States that NMOSD/MOGAD must be excluded (AQP4 and MOG antibodies) before starting a DMT, because interferon worsens NMOSD.[2]
  • Outlines the DMT ladder (injectable interferon/glatiramer, oral agents, monoclonal antibodies) and that the choice depends on disease activity, and that natalizumab carries a PML risk stratified by the anti-JC virus antibody index and treatment duration.[2][3]
  • Counsels on pregnancy: most DMTs are stopped with a washout pre-conception; glatiramer is considered the safest if treatment is needed; relapse rate falls in the third trimester and rebounds postpartum; teriflunomide, fingolimod and mitoxantrone are teratogenic and must be avoided/stopped pre-conception.[2]
  • Advises lifestyle measures: stop smoking (raises risk and accelerates progression), ensure adequate vitamin D, and a relapse safety-net — new neurological symptoms for over 24 hours warrant urgent review (and screen for infection, especially UTI).
  • Addresses driving (must report relapses affecting function; rules vary by region), and that symptoms (fatigue, spasticity, bladder, depression) are treatable with a multidisciplinary team (MS nurse, physiotherapy, occupational therapy).
  • Arranges specialist neurology follow-up, a written plan, and a clear safety-net; checks understanding and answers questions.

Model answer / expected standard

This woman has relapsing-remitting MS. The clinician should explain the diagnosis honestly but reassuringly — relapses usually recover and modern DMTs have transformed outcomes — and confirm that NMOSD/MOGAD have been excluded (AQP4 and MOG antibodies) before any DMT, because interferon worsens NMOSD. A DMT is chosen by disease activity, escalating from injectable to oral to monoclonal-antibody therapy; if natalizumab is considered, the anti-JC virus antibody index and treatment duration define the PML risk. For family planning, most DMTs are stopped pre-conception (with washout), glatiramer is the safest in pregnancy if needed, teriflunomide, fingolimod and mitoxantrone are teratogenic, and relapses fall in the third trimester and rebound postpartum. Lifestyle advice: stop smoking, ensure adequate vitamin D. Provide a relapse safety-net (new symptoms over 24 hours — present for review, check for infection), advise on driving, and arrange specialist multidisciplinary follow-up.[1][2][3]

Common errors

  • Starting a DMT without excluding NMOSD/MOGAD — interferon worsens AQP4-positive disease.
  • Failing to warn about the natalizumab PML risk and the role of the anti-JC virus antibody index.
  • Not addressing pregnancy: leaving a woman on a teratogenic DMT (teriflunomide, fingolimod, mitoxantrone) or giving no pre-conception plan.
  • Being either falsely reassuring (ignoring disability) or overly pessimistic.
  • Omitting the relapse safety-net and the need to screen for infection (UTI) at relapse.
  • Forgetting lifestyle advice (smoking cessation, vitamin D) and the multidisciplinary team.

References

The station is built on the 2017 McDonald criteria, the New England Journal of Medicine MS review, and the anti-JCV antibody stratification of natalizumab PML risk.[1][2][3]

References3Show
  1. [1]Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurology, 2018.PMID 29275977
  2. [2]Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. New England Journal of Medicine, 2018.PMID 29320652
  3. [3]Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Annals of Neurology, 2014.PMID 25273271
Multiple sclerosis — newly-diagnosed counselling OSCE station (NEET-PG/INICET) · MBBS OSCE · NeetVellum